Evaluating the best duration for maintenance therapy in light chain amyloidosis
Evaluating Maintenance In Light chain Amyloidosis (EMILIA)
This study is looking at how long patients with light chain amyloidosis should continue taking daratumumab after their initial treatment to see which duration—6 months or 18 months—helps them feel better and live longer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11034184 on NIH RePORTER |
What this research studies
This research investigates the optimal duration of maintenance therapy using daratumumab for patients with light chain amyloidosis who have responded to initial treatment. Patients who achieve a satisfactory hematological response will be randomly assigned to receive either 6 months or 18 months of daratumumab maintenance therapy. The goal is to determine which duration leads to better outcomes in terms of organ recovery and overall survival. This study aims to provide clearer guidelines for ongoing treatment in this rare condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with light chain amyloidosis who have shown a positive response to daratumumab-CyBorD induction therapy.
Not a fit: Patients who have not been treated with daratumumab-CyBorD or those with advanced organ dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols that enhance patient survival and quality of life in light chain amyloidosis.
How similar studies have performed: Previous studies have shown promising results with daratumumab in treating light chain amyloidosis, but this specific approach to maintenance therapy is novel.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Muchtar, Eli — Mayo Clinic Rochester
- Study coordinator: Muchtar, Eli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.